Immuron (IMRN) EBIT Margin (2016 - 2024)
Immuron (IMRN) posted quarterly EBIT Margin of 20861481670048.55% for Q4 2024, up 2086148167013430.0% year-over-year from N/an in Q1 2024, and up 24326835564920.37% quarter-over-quarter from 85.76% in Q4 2023.
Immuron (IMRN) EBIT Margin (2016 - 2024) Analysis & Trends
Immuron's EBIT Margin history runs 9 years deep, the most recent figure standing at 20861481670048.55% for Q4 2024.
- In Q4 2024, EBIT Margin rose 2086148167013430.0% year-over-year to 20861481670048.55%; the TTM figure through Dec 2024 stood at 15119849437479.42% (up 1511984943747964.2% YoY), while the FY2025 annual figure was 73.34%, up 4498.0% from the prior year.
- EBIT Margin for Q4 2024 stood at 20861481670048.55%, up from 85.76% in the prior quarter.
- The five-year high for EBIT Margin was 20861481670048.55% in Q4 2024, with the low at 390786883.2% in Q4 2020.
- The 5-year median for EBIT Margin is 73.09% (2023), against an average of 3476848480254.06%.
- The sharpest annual moves came in 2020 and 2024: EBIT Margin slumped 2000000000 bps in 2020, then jumped 2000000000 bps in 2024.
- Immuron's EBIT Margin stood at 390786883.2% in 2020, then soared by 100 bps to 0.0% in 2021, then sank by 7666475 bps to 60.43% in 2022, then tumbled by 42 bps to 85.76% in 2023, then jumped by 2000000000 bps to 20861481670048.55% in 2024.
- Business Quant data shows IMRN's EBIT Margin at 20861481670048.55% in Q4 2024, 85.76% in Q4 2023, and 1494.83% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Immuron | 6.81 Mn | 6.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 20,861,481,670,048.55% |
| Dec 31, 2023 | -85.76% |
| Jun 30, 2023 | -1,494.83% |
| Dec 31, 2022 | -60.43% |
| Dec 31, 2021 | 0.00% |
| Dec 31, 2020 | -390,786,883.20% |
| Dec 31, 2019 | -97.59% |
| Dec 31, 2018 | -161.71% |
| Dec 31, 2017 | 535.49% |
| Dec 31, 2016 | 481.82% |
| Jun 30, 2016 | 501.82% |